ProFactor Pharma

Transforming treatment of haemophilia

ProFactor Pharma Ltd (PFP) is developing factor VIII (FVIII) for the treatment of Haemophilia.  Our business is to manufacture low cost recombinant FVIII to a severely undersupplied world market.

According to the World Health Organisation (WHO) and the World Federation of Hemophilia around two thirds of the haemophilia patient population receive inadequate or no treatment at all.

Recent News

Outstanding technical progress

ProFactor Pharma Ltd (PFP), has completed an important development milestone in its programme to transform the treatment of ‘Haemophilia A’. The company has now received the second tranche of funding from its £2m funding round announced in September 2019 to advance...

read more

Paul Gerskowitch Joins PFP Board

Profactor Pharma Ltd is pleased to announce the appointment of Dr V Paul Gerskowitch to its board. Dr Gerskowitch joins the board of Profactor Pharma Ltd as an Investor Director with extensive, board level experience in the life sciences industries.  He currently...

read more